“8137 Background: Addition of the NK1 antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic regimen (5-HT3 antagonist + dexamethasone ( D )) in patients receiving highly emetogenic chemotherapy (Poli-Bigelli 2003; Hesketh 2003).”